Completed PHASE4 INTERVENTIONAL 1-arm NCT02321839

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.

Sponsor: Nagoya City University

Conditions Neovascular Age-related Macular Degeneration

Interventions Intraviteal Ranibizumab 0.5mg

Updated 6 times since 2017 Last updated: Aug 17, 2019 Started: Jan 31, 2014 Primary completion: Mar 31, 2019 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Neovascular Age-related Macular Degeneration, this trial is completed. The trial is conducted by Nagoya City University and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Sep 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nagoya City University
Novartis

Data source: Nagoya City University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nagoya, Japan